Andera-ye Olya

EQS-News: Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom

Retrieved on: 
Tuesday, December 26, 2023

Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.

Key Points: 
  • Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.
  • Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures.
  • Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
  • We look forward to supporting the company towards the further clinical validation of its platform.”

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

Retrieved on: 
Tuesday, November 14, 2023

BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.

Key Points: 
  • BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.
  • Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: “This oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology.
  • We are excited to support the company to continue bringing these innovative candidates closer to patients.”

EQS-News: Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Retrieved on: 
Monday, May 15, 2023

Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases

Key Points: 
  • Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
    Proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg-targeting candidates
    PARIS, FRANCE – MAY 15, 2023 – Andera Partners co-leads a €40 million Series A financing of Dualyx NV, a Ghent, Belgium based biotech developing next generation immune modulators.
  • Alongside Andera, Fountain Healthcare Partners and Forbion co-led the round, with support from existing investors V-Bio Ventures, BGV, PMV, VIB, HTGF, and GFF.
  • The funds raised will enable Dualyx to progress its lead autoimmune program DT-001, as well as its pipeline of Treg-targeting candidates.

EQS-News: Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets

Retrieved on: 
Wednesday, May 10, 2023

Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets

Key Points: 
  • Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
    MUNICH, 10 MAY 2023 – Accelerating its ambitions in the German, Austrian and Swiss (DACH) region, Andera Partners is pleased to announce the appointment of Stefan Keitel as Senior Advisor.
  • Wholly owned by its partners and management team, Andera Partners is headquartered in Paris, with offices in Milan, Munich and Antwerp.
  • Stefan Keitel commented: “I am delighted to join Andera Partners as Senior Advisor DACH region and to have the opportunity to help the firm with its development in this region.

EQS-News: Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Retrieved on: 
Wednesday, February 22, 2023

Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros

Key Points: 
  • Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
    The issuer is solely responsible for the content of this announcement.
  • With more than 3.7bn€ in assets under management, Andera Partners is quickly reaching its 2025 target of 4 to 5bn€ under management and announces a new target of 6 to 8bn€ by 2028.
  • Ahead of its business plan, Andera Partners will reach 4bn€ in assets under management in 2023, thus achieving its initial 2025 target two years ahead of schedule.
  • In announcing a new target of 6 to 8bn€ in assets under management by 2028, Andera Partners outlines its ambitions for the next five years.

EQS-News: Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO

Retrieved on: 
Wednesday, February 22, 2023

PARIS, FRANCE – FEBRUARY 14, 2023 – Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announces that its portfolio company Mineralys Therapeutics completed last Friday an oversubscribed and upsized $192 million initial public offering (IPO) on the Nasdaq Global Select Market at $16.00 per share.

Key Points: 
  • PARIS, FRANCE – FEBRUARY 14, 2023 – Andera Partners, a leading European private equity player, through its practice Andera Life Sciences, focused on investments in companies developing breakthrough therapeutics and medical technologies, announces that its portfolio company Mineralys Therapeutics completed last Friday an oversubscribed and upsized $192 million initial public offering (IPO) on the Nasdaq Global Select Market at $16.00 per share.
  • Andera co-led the company’s $118 million Series B financing in June 2022 and re-invested into the oversubscribed IPO financing.
  • The IPO financing will support the company to advance its pivotal program in uncontrolled hypertension in the United States.
  • Through this IPO on Nasdaq, Andera Partners supported again the growth of its portfolio companies through public market financing.

EQS-News: Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches

Retrieved on: 
Thursday, February 2, 2023

Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches

Key Points: 
  • Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches
    The issuer is solely responsible for the content of this announcement.
  • The financing was co-led by Pfizer Ventures and Earlybird Venture Capital, and also included investment from new investors Oxford Science Enterprises and British Patient Capital and existing investors Canaan and Andera Partners.
  • Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of novel cancer antigens.
  • In conjunction with the financing, Grey Wolf Therapeutics has announced several new appointees to its board of directors including:

EQS-News: Andera Partners raises its largest life sciences fund at €456M, demonstrating the attractiveness of its activity and of the sector

Retrieved on: 
Monday, October 10, 2022

Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector

Key Points: 
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    The issuer is solely responsible for the content of this announcement.
  • Andera Partners raises its largest life sciences fund at 456M, demonstrating the attractiveness of its activity and of the sector
    PARIS, 10 OCTOBER 2022 Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.
  • The sixth generation of BioDiscovery funds is consolidating Andera Partners position as one of the leading players in life sciences venture capital in Europe.
  • Its teams manage over 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

DGAP-News: Andera Partners strengthens its Life Sciences team with a new partner

Retrieved on: 
Thursday, July 7, 2022

PARIS, JULY 7, 2022 - Andera Partners strengthens its organization by welcoming Jan Van den Bossche as a partner within Andera Life Sciences, its team specialized in innovative therapeutics and medical devices.

Key Points: 
  • PARIS, JULY 7, 2022 - Andera Partners strengthens its organization by welcoming Jan Van den Bossche as a partner within Andera Life Sciences, its team specialized in innovative therapeutics and medical devices.
  • Jan Van den Bossche, partner at Andera Life Sciences, says: "I am very pleased to join the Andera Life Sciences team, one of the most renowned European funds in the sector.
  • The Andera Life Sciences team is now composed of 15 professionals including 5 partners and 3 venture partners.
  • Its teams manage almost 3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

Retrieved on: 
Monday, June 13, 2022

The Company also will apply the capital to investigate ICT01 in combination with other therapeutic agents, including IL-2, in the forthcoming EVICTION-2 clinical trial.

Key Points: 
  • The Company also will apply the capital to investigate ICT01 in combination with other therapeutic agents, including IL-2, in the forthcoming EVICTION-2 clinical trial.
  • The funding will accelerate the further advance toward the clinic of additional antibody candidates in immuno-oncology, auto-immune and infectious diseases.
  • In conjunction with the financing round, Florent Gros (Earlybird) and Raphal Wisniewski (Andera Partners) will join the Companys Board of Directors.
  • Hans Henrik Christensen, Chief Financial Officer of ImCheck Therapeutics, added, ImCheck has raised a total of EUR 154 million since inception.